Current Knowledge | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
The production of reactive oxygen intermediates and reactive
nitrogen intermediates by innate immune cells is considered
to be an effective host-defense mechanism against microbial
pathogens. In the murine model of tuberculosis (TB), nitric
oxide (NO) plays an essential role in the killing of Mycobacterium tuberculosis by mononuclear phagocytes. For example, in
the mouse strain with a genetic disruption for inducible NO
synthase (iNOS
/
), infection with M. tuberculosis is associated with a significantly higher risk of dissemination and mortality. Although more controversial in humans, there is a
growing body of evidence that NO produced by TB-infected
macrophages and by epithelial cells also has antimycobacterial effects against M. tuberculosis. The precise mechanism(s)
by which NO and other reactive nitrogen species antagonize
M. tuberculosis is not known, but may involve disruption of
bacterial DNA, proteins, signaling, and/or induction of apoptosis of macrophages that harbor mycobacteria. In addition to
cytokines such as tumor necrosis factor-
and interleukin 1-
,
mycobacterial cell wall components such as lipoarabinomannan and 19 kD lipoprotein, along with the T-cell-derived interferon-
, may also induce NO expression. In a Darwinian
fashion, it also appears that certain strains of M. tuberculosis
have evolved strategies to combat the toxic effects of NO.
| |
NO in Host Defense Against Microbial Pathogens |
|---|
|
|
|---|
In immunocompetent individuals, the innate and adaptive
arms of the immune system are relatively efficient in containing and killing Mycobacterium tuberculosis. It is estimated that of 100 people newly infected with the tubercle
bacilli, only about 5-10 individuals will develop tuberculosis (TB) over their lifetime (1). Host cells that are protective
against TB include macrophages, dendritic cells (DC),
T-lymphocytes, and airway epithelial cells. The production
of reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI) by innate immune cells is considered to be a relatively effective host-defense mechanism
against microbial pathogens. Catalytic action of the respiratory burst by the nicotinamide adenine dinucleotide
phosphate (NADPH)-oxidase complex produces ROI such
as hydrogen peroxide (H2O2), superoxide anion (O2
),
and hydroxyl radical (OH·). The importance of ROI in antimicrobial defense is exemplified in patients with chronic
granulomatous disease (CGD), a disorder due to a mutation in any one of the four subunits of NADPH-oxidase complex, resulting in an inability to generate ROI. Humans with CGD are unusually susceptible to pyogenic infections with Staphylococcus aureus, Aspergillus species,
and Nocardia species (2). Although the incidence of mycobacterial infections is not considered to be increased in
CGD patients (2), TB appears to be a problematic issue in
these patients in areas endemic for TB (3). For example, Lau and colleagues (3) estimated that in Hong Kong, the
annual incidence of TB in CGD patients was > 170 times
that for the general population. In three neonates with
CGD who received bacillus Calmette-Guerin (BCG) as an
immunogen, disseminated disease due to this mycobacteria developed (4). In the X-linked CGD mice (X-CGD), a
strain with a genetic disruption to the gp91phox subunit of
NADPH-oxidase, M. tuberculosis growth was markedly enhanced in the lungs compared with the background B6
mice (5). However, when infected X-CGD macrophages
were stimulated with interferon (IFN)-
, the RNI produced was able to inhibit M. tuberculosis growth. In contrast, other studies found ROI to be relatively ineffective
in killing M. tuberculosis (6).
The high output expression of nitric oxide (NO) in response to cytokines or to pathogen-derived molecules is an important component in the host defense against intracellular microorganisms as diverse as Toxoplasma gondii, Leishmania major, Listeria monocytogenes, Plasmodium species, Ectromelia virus, Coxsackie B3 virus, M. leprae, and M. tuberculosis (7). NO is formed when the guanidino nitrogen of L-arginine is oxidized by a family of isoenzymes known as NO synthases (NOSs). Exposure to NO at low concentrations, e.g., < 100 ppm, killed more than 99% of M. tuberculosis in culture (11).
The potential mechanisms by which NO may affect antimicrobial activity are protean. NO and other RNI can
modify bacterial DNA, protein, and lipids at both the microbial surface and intracellularly. NO can also deaminate
as well as directly damage bacterial DNA, generating abasic sites and strand breaks. Other potential mechanisms of
killing by NO include interaction with accessory protein
targets such as iron-sulfur groups, heme group, thiols, aromatic or phenolic residues, tyrosyl radicals, and amines,
resulting in enzymatic inactivation or other protein malfunctions (12). Peroxynitrite, ONOO
, can also mediate
nitrosylation of tyrosine residues, and therefore has the
potential to disrupt tyrosine phosphorylation-dependent signaling pathways (8).
Since M. tuberculosis may find a haven in macrophages,
macrophage apoptosis is considered by many to be necessary to initiate mycobacterial killing; NO may induce such
apoptosis. The mechanism by which macrophage apoptosis induced killing of M. bovis BCG was by facilitating the
fusion of the mycobacterial-containing vacuoles to lysosomes,
thereby subverting the mycobacterial control to prevent
such a lethal fusion (13). Another potential mechanism for
the apoptosis-induced mycobacterial killing is that, as with host nuclear fragmentation, mycobacterial DNA may also
be destroyed during apoptosis (13). The mechanism by which
the natural resistance associated macrophage protein (Nramp)
locus confers resistance to M. tuberculosis may be related, in
part, to NO. Macrophage cell lines have been derived with
either the wildtype Nramp (B10R), a strain that is resistant
to M. tuberculosis, or the Nramp mutation (B10S), a strain
that is susceptible to the tubercle bacillus. In B10R macrophages infected with H37Rv M. tuberculosis, the induction of apoptosis and subsequent killing of M. tuberculosis directly correlated with NO production (14). This induction
of apoptosis appeared to be dependent on metabolically
active mycobacteria because killed M. tuberculosis rescued
macrophages from apoptosis (14). Furthermore, this process is TNF-
-dependent because neutralization of TNF-
diminished both NO production and apoptosis (15). Although B10R macrophages also produced greater amounts
of O2
than the susceptible B10S macrophages after infection with M. tuberculosis, ROI scavengers did not inhibit
apoptosis or alter mycobacterial viability (16). Despite the
accumulation of these potential effects of NO, the prime
mechanism(s) by which NO or other RNI kill M. tuberculosis is still not fully understood.
In addition to mammalian host-cell factors, various M. tuberculosis strains also have differential susceptibility to
the different species of RNIs. O'Brien and colleagues (17)
found the relative in vitro resistance of various M. tuberculosis strains to sodium nitrite directly correlated with the
virulence of the strains in guinea pigs. Rhoades and Orme
(18) studied virulent strains of M. tuberculosis and found
that intracellular NO2
production by macrophages was
more likely to be bacteriostatic than bactericidal. In mycobacteria exposed to various RNIs, NO and NO2 exhibited
antimycobactericidal activity against either BCG or a virulent strain of M. tuberculosis, with NO2 significantly more
potent than NO (19). Interestingly, whereas BCG was susceptible to ONOO
, the Erdman strain of M. tuberculosis
and a clinical isolate M160 were resistant to it. A possible
mechanism for the ONOO
resistance is by the ability of
M. tuberculosis peroxiredoxin alkylhydroperoxide reductase subunit C (AhpC) to catalytically detoxify ONOO
(20).
These findings further illustrate the specificity of RNI in
regard to their effects on different species or strains of mycobacteria. Nathan and Shiloh (8) reported a preliminary observation that drugs that appear to cure M. tuberculosis
infection in immunocompetent mice failed to do so in iNOS-deficient mice, suggesting that tuberculocidal drugs may
be effective in vivo only with help from iNOS-derived NO.
| |
Role of NO in Rodent Host-Defense against TB |
|---|
|
|
|---|
In the murine model of TB, NO plays an essential role in
the killing of M. tuberculosis by mononuclear phagocytes
(7, 10, 21). Intratracheal administration of virulent M. tuberculosis to rats stimulated iNOS and NO production in
alveolar macrophages (22). Moreover, administration of
the NOS inhibitor L-NG-monomethylarginine (L-NMMA)
intraperitoneally attenuated the M. tuberculosis-induced increase in RNI in lung homogenates and bronchoalveolar
fluid. One of the best examples of the protective role of
NO in murine TB is illustrated by the genetically disrupted
iNOS mouse strain (iNOS
/
), where infection with M. tuberculosis was associated with a significantly higher risk
of dissemination and mortality compared with the wild-type C57BL/6 mice (5, 21). In mice that express the Bcg/
Nramp-1 resistance gene to M. tuberculosis, NO also mediated this resistance (23). Recent work indicates that preventing reactivation of latent infection appears to be under the control of both RNI and non-RNI pathways (24,
25). In murine models of latent infection, administration
of the NOS inhibitor aminoguanidine led to the development of reactivation TB, although a non-RNI pathway also
seemed to be involved. In a more recent study, depletion
of CD4(+) T cells in a mouse model of latent infection revealed that although CD4 was required for preventing reactivation disease, it was by an iNOS- and IFN-
-independent antimycobacterial mechanism (24). These experimental findings indicate both NO-dependent and NO-independent mechanisms are operative to maintain the latent state, although
the applicability of these results to humans is uncertain.
| |
Role of NO in Human Host-Defense against TB |
|---|
|
|
|---|
In contrast to the murine models of TB, there is a greater
controversy on the role of NO in killing or limiting the
growth of M. tuberculosis in humans (8). Aston and colleagues (26) showed that in vitro, the early mycobacteriostatic activity of human alveolar macrophages following
M. tuberculosis infection was NO-independent. Interestingly, they also noted that exogenous IFN-
failed to inhibit mycobacterial growth by human alveolar macrophages. Nevertheless, there is a growing body of evidence that NO produced by TB-infected human macrophages
and by epithelial cells is also antimycobacterial against M. tuberculosis (27). Previously, it was thought that human macrophages did not produce NO in response to inflammatory stimuli. However, three experimental issues
have shed light on this apparent paradox and it is now abundantly clear that human macrophages do make NO
from increased iNOS activity. First, the difficulty in detecting NO in human macrophages may be due to the lack of
tetrahydrobiopterin with in vitro cultures, a necessary co-factor for iNOS catalytic activity and a co-enzyme not constitutively synthesized by human monocytes or macrophages (32). However, the circumstances are different in
vivo because human macrophages may obtain tetrahydrobiopterin from other neighboring cells capable of synthesizing it, such as activated lymphocytes and endothelial
cells (32). Second, Jagannath and coworkers (31) recently
demonstrated that the difficulty in detecting NO in human
macrophages may, in part, be due to the inability of the
standard colorimetric assay to detect relatively low levels
of NO2
. Using a more sensitive fluorometric assay, they
showed that NO was detectable in peripheral blood monocyte-derived macrophages infected with M. tuberculosis
(31). Furthermore, they demonstrated the significance of
this NO production by showing that iNOS inhibition with
L-NMMA resulted in enhanced M. tuberculosis growth in
human macrophages (31). Recently, Wang and coworkers
(33) showed that cultured peripheral blood monocyte isolated from patients with active TB not only had increased
iNOS expression compared with cells from normal subjects, but also had increased spontaneously released NO2
in culture medium (7,513 ± 4,868 nmol/106 cells versus
45.3 ± 13.1 nmol/106 cells). Third, as noted by Nathan and
Shiloh (8), it may have been overlooked that few, if any,
have reported the induction of NO in macrophages derived from murine blood monocytes. In other words, the
primary anatomic source of the macrophages used in in
vitro experiments may have a profound impact on whether
certain genes such as iNOS are expressed or active due to
differences in the state of differentiation of the macrophages. This concept is supported by studies of Weinberg
and colleagues (34), who demonstrated that human peripheral blood monocytes stimulated with LPS or various
proinflammatory cytokines have no increase in NO production over basal levels, whereas human peritoneal macrophages have significantly enhanced NOS activity and
NO2
/NO3
production after LPS and/or IFN-
stimulation.
Another example of this "site-specific" phenotype of
macrophages is that bone marrow-derived macrophages
from the C3H/HeJ mice, which has natural mutation of
Toll-like receptor 4, do not respond to LPS, whereas alveolar macrophages from the same mice are LPS-responsive
(35). Rich and coworkers (27) also showed that in alveolar
macrophages from normal volunteers, iNOS and NO were
inducible after M. tuberculosis infection and that there was
an inverse correlation between the magnitude of intracellular growth and the amount of NO produced. Bonecini-Almeida and colleagues (36) showed that iNOS was inducible in IFN-
-primed monocyte-derived macrophages that
are infected with M. tuberculosis. There was greater iNOS
induction when the infected macrophages were cocultured with M. tuberculosis lysate/IFN-
-primed peripheral blood
lymphocytes. Nicholson and coworkers (29) demonstrated
increased iNOS protein expression in alveolar macrophages
from TB patients. Moreover, they showed by a diaphorase
cytochemistry assay that the iNOS was catalytically active,
providing proof that there was high-output NO production
in TB-infected macrophages (29). An immunofluorescence assay showed increased production of iNOS and ONOO
in M. bovis-inoculated human alveolar macrophages and
inhibition of NOS activity with L-NMMA treatment markedly reduced killing efficiency of mycobacteria (37). Kim
and coworkers (30) observed that peripheral blood mononuclear cells (PBMC) infected with M. tuberculosis produced NO, and that the avirulent H37Ra strain induced
significantly higher levels than the virulent H37Rv strain. In the human promyelocytic cell line HL-60, vitamin D3,
known to have some therapeutic effect against TB, suppressed the growth of M. tuberculosis via the production of
NO (28). Kuo and colleagues (38) showed that alveolar
macrophages from TB patients produced increased amounts
of NO compared to healthy control subjects. Furthermore,
NO played an autoregulatory role in amplifying the synthesis of TNF-
and IL-1
(38). Wang and coworkers (39) demonstrated that the increased exhale NO in patients
with TB was due to upregulation of iNOS in alveolar macrophages. In addition, the amount of exhaled NO correlated with the capacity of the alveolar macrophages in
vitro to produce NO. NO is not only mycobactericidal but
may also participate in the formation of protective tissue granulomas (40). In a preliminary experiment, Raju and
coworkers (41) showed that aerosolized IFN-
increased
NO levels in the bronchoalveolar lavage fluids in patients
with active TB. In an intriguing epidemiologic study,
Friedman and colleagues (42) reported that the drug-susceptible but more virulent C-strain of M. tuberculosis,
which caused widespread dissemination in an at-risk population and accounted for a large proportion of new TB
cases in New York City, was resistant to RNI, whereas
thirteen other unrelated isolates were susceptible to RNI.
The investigators speculated that the RNI-resistant C-strain
had a biologic advantage over the RNI-susceptible isolates,
resulting in a greater likelihood of progressively active disease with the C-strain. Collectively, these studies provide
evidence that NO likely plays a contributory role in human host defense against M. tuberculosis.
| |
Role of Epithelial Cells in NO Expression |
|---|
|
|
|---|
High output NO production by iNOS may also occur in
human lung epithelial cells (43). Airway epithelial cells exposed to M. tuberculosis have been shown to produce chemokines such as IL-8 and regulated on activation, normal
T-cells expressed and secreted (RANTES) (43). The co-addition of culture supernatant fluid from M. tuberculosis-infected PBMC plus exogenous IFN-
to A549 airway epithelial cells induced NO in a TNF-
- and IL-1
-dependent fashion (44). Pasula and colleagues (45) showed that surfactant protein A (SP-A), although able to enhance the attachment of M. tuberculosis to macrophages by acting as a
ligand, inhibited M. tuberculosis-induced RNI expression
in macrophages.
| |
Role of Dendritic Cells in NO Production |
|---|
|
|
|---|
Lung dendritic cells (DC) are key antigen-presenting cells
capable of triggering specific T-cell responses to inhaled
pathogens, including mycobacteria. In turn, the effector T
cells produce cytokines that activate alveolar macrophages
and lyse target cells in an effort to eliminate the pathogen.
M. bovis-infected DC, when instilled into mice trachea,
protected the mice from subsequent aerosol M. tuberculosis infection (46). Due to their antigen presentation, DC
play an essential role in the initiation of primary T-cell responses to foreign antigens. Human or mouse DC are also capable of phagocytosing M. tuberculosis with subsequent
increases in the cell surface expression of several inflammatory cytokines (IL-6, IL-1
, and IL-12), co-stimulatory
molecules (CD54, CD40, and B7.1), and class I MHC molecules (47, 48). One important experimental caveat to
bear in mind with DC is that their isolation requires elaborate negative selection with monoclonal antibody and prolonged culture in cytokine-enriched milieu, which may ultimately alter their functions in vitro compared with the in
vivo state.
The literature is replete with studies showing that DC
have the capacity to produce NO in the context of a variety of biologic functions. In the rat thymus, DC-induced
NO expression mediates thymic cell selection by inducing
apoptosis in thymocytes that encounter self-antigens (49).
Mouse bone marrow-derived DC were also shown to produce NO in response to IFN-
+ LPS (50). Kradin and coworkers (51) showed that in response to heat-killed Listeria, rat alveolar macrophages with DC characteristics
produced NO. Stenger and colleagues (52) showed that
C57BL/6 mice with acute cutaneous leishmaniasis had increased iNOS activity present in both macrophages and
DC, cell types important in controlling the infection. Although Chambers and coworkers (53) showed that the expression of iNOS, IFN-
, and the number of DC and
monocytes were all increased in lymph nodes draining the
site of live BCG vaccination, the significance of the iNOS
and whether or not the increased iNOS was due to the DC
were not known. In comparing the ability of DC and macrophages generated from the bone marrow cells of C57BL/6
mice to kill M. tuberculosis, Bodnar and colleagues (54)
showed that both activated DC and macrophages inhibited the growth of intracellular mycobacteria in an iNOS-dependent fashion. In contrast, however, while this activation
enabled macrophages to kill the mycobacteria, the tubercle bacilli within activated DC were not killed. This difference occurred despite the fact that there was essentially
similar levels of RNI produced in DC and in macrophages.
The mechanism for this inability of DC to kill M. tuberculosis is not fully understood, but may be due to persistence
of the bacilli in special vacuoles in DC. The implication is
that DC may serve as a reservoir for M. tuberculosis in tissues and use this cell as a vehicle for dissemination from
the lung to the lymph nodes and other organs (54).
| |
Role of T Cells in NO Expression and the Effects of M. tuberculosis-Induced NO on T-Cells |
|---|
|
|
|---|
The antigen-presenting cell-T-cell interaction is a fundamental process that links the innate and adaptive arms of
the immune system in a synergistic fashion. Upon such interaction, mutual induction of cytokines occurs, such as
IL-12 and IL-18 from macrophages and IFN-
from activated CD4(+) T cells and possibly from macrophages (55).
IFN-
may also be produced by CD8(+) cytotoxic T-cells. IFN-
is an essential cytokine in iNOS-NO induction by
LPS, TNF-
, IL-1
, and lipoglycans of M. tuberculosis.
Cooper and colleagues (56) suggested in a murine lung infection model that IFN-
expression by CD8(+) T-cells
may be the primary mechanism for the protective role of
these cells rather than via cell lysis molecules such as perforin or granzyme.
Interaction of CD40 ligand present on activated T cells
and CD40 present on B cells, macrophages, and other antigen-presenting cells is important in the control of intracellular pathogens (e.g., Leishmania spp and Toxoplasma
gondii) through enhanced expression of IFN-
, TNF-
,
IL-12, and NO (57). In contrast, CD40 ligand is not essential for the development of murine cell-mediated immunity and resistance to M. tuberculosis or H. capsulatum
as evinced by mice with genetic disruption for CD40 ligand
(CD40L
/
) (60, 61). In fact, spleen cells from CD40L
/
mice stimulated with M. tuberculosis produced IL-12, TNF-
,
and NO levels comparable to control mice cells. These
findings would suggest that redundant pathways exist for
the expression of these host-defense mediators. In a human correlate, individuals with a defective CD40 ligand
gene may develop a high-IgM syndrome and display increased susceptibility to infection with Cryptococcus neoformans, Pneumocystis carinii, and Histoplasma capsulatum (62). However, the role of CD40-CD40 ligand in
human host-defense against TB remains unknown.
Sciorati and colleagues (63) showed that NO produced
by M. tuberculosis-infected macrophages following CD95-
CD95 ligand interaction inhibited apoptosis of gamma-delta (
) T cells. Thus, NO may prolong the life span of
activated 
T cells, strengthening the link between the innate and adaptive immunity against TB. In contrast, macrophages from mice chronically infected with M. tuberculosis suppressed the number of CD4 (+) T cells and their nonspecific and PPD-specific proliferative responses through
production of NO (64). The mechanism of the NO production was shown to be IFN-
-dependent because in BCG-infected mice with genetic disruption of IFN-
, the activated
CD4 (+) T cells did not undergo apoptosis. However, reconstitution with exogenous IFN-
to cultured splenocytes from BCG-infected IFN-
knockout mice induced NO-mediated apoptosis of activated CD4 (+) T cells (65).
| |
Inducers of NO Expression in the Context of M. tuberculosis |
|---|
|
|
|---|
iNOS and NO expression is induced by a wide variety of
cytokines and inflammatory mediators such as TNF-
,
IFN-
, LPS, IL-1
, hypoxia, and picolinic acid (reviewed
in [66]). However, mycobacterial cell wall components are
also capable of eliciting host-inflammatory responses. Surrounding the plasma membrane of M. tuberculosis is a
layer of cross-linked peptidoglycan. Protruding from the peptidoglycan layer are macromolecules that include mycolic acid-arabinogalactan peptidoglycan complexes and lipoarabinomannan (LAM). LAM is comprised of a linear
series of ringed mannose sugar residues, with periodic branches of single mannoses. At the proximal end of LAM,
a phosphatidylinositol group anchors it to the plasma membrane. Distal to the mannose residues are attached a linear
series of arabinoses. In M. tuberculosis, these arabinose
residues are further "capped" to various degrees with mannoses. Adams and coworkers (67) showed that the LAM derived from the Erdman strain of M. tuberculosis, in conjunction with IFN-
, induced NO expression in mouse
peritoneal macrophages. LAM is also known to induce
TNF-
and IL-1
, cytokines capable of inducing NO expression (68, 69). In addition, M. tuberculosis LAM is also
directly capable of inducing iNOS-NO expression in a
mouse macrophagic cell line RAW 264.7 that is poorly responsive to TNF-
or IL-1
(70). Also anchored to the
plasma membrane are simpler precursors of LAM such as
the disaccharide dimannosylphosphatidylinositides (PIM2)
and lipomannan (LM), the latter comprised of a phosphatidylinositol group linked to a mannan core. Barnes
and coworkers (71) demonstrated that PIM2 or LM were
able to induce inflammatory and antiinflammatory molecules such as TNF
, GM-CSF, IL-1
, IL-1
, IL-6, IL-8,
and IL-10. Recently, Brightbill and colleagues (72) showed
that the 19-kDa lipoprotein of M. tuberculosis, also a mycobacterial cell wall component, induced iNOS and NO expression. In an autocrine or paracrine fashion, extracellular nucleotides such as ATP released from M. tuberculosis-infected
macrophages may also induce NO production by engagement of P2 purinergic receptors (73). Teleologically, this
unique mechanism of NO induction may limit the expression of NO locally to sites of infection, sparing unaffected
tissues the potentially injurious effects of NO.
| |
Mycobacterial Responses to NO |
|---|
|
|
|---|
M. tuberculosis has also evolved clever ways to evade the
toxic effects of RNI. Ehrt and coworkers (74) showed that
a novel M. tuberculosis gene, noxR1, conferred resistance
to the toxic effects of RNI, although the precise mechanism is not known. This same group later showed that the
M. tuberculosis noxR3 gene also protected bacteria from
the toxic effects of ROI and RNI (75). Similarly, the M. tuberculosis-derived peroxiredoxin gene Ahpc (alkyl hydroperoxide reductase subunit C) prevented RNI-induced necrosis and apoptosis in human cells (76). Ahpc has also
been shown to detoxify ONOO
to NO2
(20). NO may
also induce the expression of a M. tuberculosis-derived 16-kDa heat shock protein, a molecule that promotes stationary phase of growth of mycobacteria (77). In hypoxic conditions, nitrate (NO3
), a degradation product of NO, is
reduced by the tubercle bacilli to nitrite (NO2
) at a rate
that is significantly greater than in aerobic conditions. This
induction of nitrate reductase under hypoxic conditions
may serve a respiratory function in supporting the shift of
the tubercle bacilli from aerobic growth to a state of dormancy (78).
| |
Summary |
|---|
|
|
|---|
Unlike the adaptive arm of the immune system, NO is a
nonspecific, chemically reactive molecule that is important
in host defense against a wide variety of microbial pathogens. However, it is also becoming increasingly clear that
no one killing mechanism or cell type is sufficient to kill
mycobacteria in vivo. For example, cell lytic molecules
such as granzyme, granulysin, and perforin may also contribute in the killing of M. tuberculosis (79). Although
O2
appears not to be required in rodents, the lack of a
role for O2
or its products (such as ONOO
) has not
been definitively proven in humans. Nevertheless, a substantial body of evidence now exists that implicates a participatory role for NO in human host defense against M. tuberculosis. Defining the relative importance of NO in
host defense as compared with other molecules is difficult,
although it appears that certain strains of M. tuberculosis
have evolved strategies to combat the toxic effects of NO.
It is paramount that future work should not only further
define the role of NO in relevant human cells, such as alveolar macrophages and airway epithelial cells, but also under conditions that best mimic the in vivo environment,
such as co-culture of the relevant cells. Such studies, which
refine our understanding of the importance and exact role
of NO in defense against TB, may lead to innovative vaccination or treatment strategies.
| |
Footnotes |
|---|
Address correspondence to: Edward D. Chan, M.D., Assistant Professor of Medicine, K613e, Goodman Building, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail: chane{at}njc.org
(Received in original form January 2, 2001 and in revised form June 8, 2001).
Abbreviations: dendritic cells, DC; interferon, IFN; interleukin, IL; inducible nitric oxide synthase, iNOS; lipomannan, LAM; mannose-capped lipoarabinomannan, ManLAM; nitric oxide, NO; nitrogen dioxide, NO2; superoxide anion, O2
; peroxynitrite anion, ONOO
; dimannosylphosphatidylinositides, PIM2; reactive nitrogen intermediates, RNI; reactive oxygen intermediates, ROI; tuberculosis, TB; tumor necrosis factor, TNF.
| |
References |
|---|
|
|
|---|
1. Toossi, Z., and J. J. Ellner. 2000. Pathogenesis of tuberculosis. In Tuberculosis: Current Concepts and Treatment. L. N. Friedman, editor. CRC Press LLC, Boca Raton, FL. 19-47.
2. Segal, B. H., T. L. Leto, J. I. Gallin, H. L. Malech, and S. M. Holland. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine 79: 170-200 [Medline].
3. Lau, Y. L., G. C. F. Chan, S. Y. Ha, Y. F. Hui, and K. Y. Yuen. 1998. The role of phagocytic respiratory burst in host defense against Mycobacterium tuberculosis. Clin. Infect. Dis. 26: 226-227 [Medline].
4. Johnston, R. B., and S. L. Newman. 1977. Chronic granulomatous disease. Ped. Clin. North Am. 24: 365-376 . [Medline]
5. Adams, L. B., M. C. Dinauer, D. E. Morgenstern, and J. L. Krahenbuhl. 1997. Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tuberc. Lung Dis. 78: 237-246 [Medline].
6. Jones, G. S., H. J. Amirault, and B. R. Andersen. 1990. Killing of M. tuberculosis by neutrophils: a nonoxidative process. J. Infect. Dis. 162: 700-704 [Medline].
7.
Chan, J.,
Y. Xing,
R. S. Magliozzo, and
B. R. Bloom.
1992.
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
J. Exp. Med.
175:
1111-1122
8.
Nathan, C., and
M. U. Shiloh.
2000.
Reactive oxygen and nitrogen intermediates in the relationship between hosts and microbial pathogens.
Proc.
Natl. Acad. Sci. USA
97:
8841-8848
9. Fang, F. C.. 1997. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 100: S43-S50 .
10. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63: 736-740 [Abstract].
11. Long, R., B. Light, and J. A. Talbot. 1999. Mycobacteriocidal action of exogenous nitric oxide. Antimicrobiol. Agents. Chemo. 43: 403-405 .
12. Gow, A. J., R. Foust, S. Malcolm, M. Gole, and H. Ischiropoulos. 1999. Biochemical regulation of nitric oxide cytotoxicity. In Nitric Oxide and Infection. F. C. Fang, editor. Kluwer Academic/Plenum Publishers, New York. 175-187.
13. Molloy, A., and G. Kaplan. 1996 Cell-mediated immune response in tuberculosis. In Tuberculosis. W. N. Rom and S. M. Garay, editors. 305-314.
14. Rojas, M., L. F. Barrera, G. Puzo, and L. F. Garcia. 1997. Differential induction of apoptosis by virulent Mycobacterium tuberculosis in resistant and susceptible murine macrophages: role of nitric oxide and mycobacterial products. J. Immunol. 159: 1352-1361 [Abstract].
15.
Rojas, M.,
M. Olivier,
P. Gros,
L. F. Barrera, and
L. F. Garcia.
1999.
TNF-alpha and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages.
J. Immunol.
162:
6122-6131
16. Rojas, M., L. F. Barrera, and L. F. Garcia. 1998. Induction of apoptosis in murine macrophages by Mycobacterium tuberculosis is reactive oxygen intemediates-independent. Biochem. Biophys. Res. Comm. 247: 436-442 [Medline].
17.
O'Brien, L.,
J. Carmichael,
D. B. Lowrie, and
P. W. Andrew.
1994.
Strains
of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen
intermediates in vitro.
Infect. Immun.
62:
5187-5190
18. Rhoades, E. R., and I. M. Orme. 1997. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65: 1189-1195 [Abstract].
19. Yu, K., C. Mitchell, Y. Xing, R. S. Magliozzo, B. R. Bloom, and J. Chan. 1999. Toxicity of nitrogen oxides and related oxidants on mycobacteria: M. tuberculosis is resistant to peroxynitrite anion. Tuberc. Lung Dis. 79: 191-198 [Medline].
20. Bryk, R., P. Griffin, and C. Nathan. 2000. Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature 407: 211-215 [Medline].
21.
MacMicking, J. D.,
R. J. North,
R. LaCourse,
J. S. Mudgett,
S. K. Shah, and
C. F. Nathan.
1997.
Identification of nitric oxide synthase as a protective
locus against tuberculosis.
Proc. Natl. Acad. Sci. USA
94:
5243-5248
22. Greenberg, S. S., J. Xie, J. Kolls, C. Mason, and P. Didier. 1995. Rapid induction of mRNA for nitric oxide synthase II in rat alveolar macrophages by intratracheal administration of Mycobacterium tuberculosis and Mycobacterium avium. Proc. Soc. Exp. Biol. Med. 209: 46-53 .
23. Arias, M., M. Rojas, J. Zabaleta, J. I. Rodriguez, S. C. Paris, L. F. Barrera, and L. F. Garcia. 1997. Inhibition of virulent Mycobacterium tuberculosis by Bcg (r) and Bcg (s) macrophages correlates with nitric oxide production. J. Infect. Dis. 176: 1552-1558 [Medline].
24.
Scanga, C. A.,
V. P. Mohan,
K. Yu,
H. Joseph,
K. Tanaka,
J. Chan, and
J. L. Flynn.
2000.
Depletion of CD4+ T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon
and nitric
oxide synthase 2.
J. Exp. Med.
192:
347-358
25.
Flynn, J. L.,
C. A. Scanga,
K. E. Tanaka, and
J. Chan.
1998.
Effects of aminoguanidine on latent murine tuberculosis.
J. Immunol.
160:
1796-1803
26.
Aston, C.,
W. N. Rom,
A. T. Talbot, and
J. Reibman.
1998.
Early inhibition
of mycobacterial growth by human alveolar macrophages is not due to nitric oxide.
Am. J. Respir. Crit. Care Med.
157:
1943-1950
27. Rich, E. A., M. Torres, E. Sada, C. K. Finegan, B. D. Hamilton, and Z. Toossi. 1997. Mycobacterium tuberculosis (MTB)-stimulated production of nitric oxide by human alveolar macrophages and relationship of nitric oxide production to growth inhibition of MTB. Tuberc. Lung. Dis. 78: 247-255 [Medline].
28.
Rockett, K. A.,
R. Brookes,
I. Udalova,
V. Vidal,
A. V. Hill, and
D. Kwiatkowski.
1998.
1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and
suppresses growth of Mycobacterium tuberculosis in a human macrophage-like cell line.
Infect. Immun.
66:
5314-5321
29.
Nicholson, S.,
M. da Gloria,
Bonecini-Almeida,
J. R. Lapa e Silva,
C. Nathan,
Q.-W. Xie,
R. Mumford,
J. R. Widner,
J. Calaycay,
J. Geng,
N. Boechat,
C. Linhares,
W. Rom, and
J. L. Ho.
1996.
Inducible nitric oxide
synthase in pulmonary alveolar macrophages from patients with tuberculosis.
J. Exp. Med.
183:
2293-2302
30. Kim, H. C., J. H. Kim, J. W. Park, G. Y. Suh, M. P. Chung, O. J. Kwon, C. H. Rhee, and Y. C. Han. 1997. Difference of nitric oxide production in peripheral blood mononuclear cells and airway epithelial cells between healthy volunteer and patients with tuberculosis. Tubercul. Respir. Dis. 44: 72 .
31. Jagannath, C., J. K. Actor, and R. L. J. Hunter. 1998. Induction of nitric oxide in human monocytes and monocyte cell lines by Mycobacterium tuberculosis. Nitric Oxide 2: 174-186 . [Medline]
32. Bertholet, S., E. Tzeng, E. Felley-Bosco, and J. Mauel. 1999. Expression of the inducible NO synthase in human monocytic U937 cells allows high output nitric oxide production. J. Leuk. Biol. 65: 50-58 [Abstract].
33. Wang, C.-H., H.-C. Lin, C.-Y. Liu, K.-H. Huang, T.-T. Huang, C.-T. Yu, and H.-P. Kuo. 2001. Upregulation of inducible nitric oxide synthase and cytokine secretion in peripheral blood monocytes from pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 5: 283-291 [Medline].
34.
Weinberg, J. B.,
M. A. Misukonis,
P. J. Shami,
S. N. Mason,
D. L. Sauls,
W. A. Dittman,
E. R. Wood,
G. K. Smith,
B. McDonald,
K. E. Bachus,
A. F. Haney, and
D. L. Granger.
1995.
Human monoclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages.
Blood
86:
1184-1195
35. Ryan, L. K., and M. W. Vermeulen. 1995. Alveolar macrophages from C3H/ HeJ mice show sensitivity to endotoxin. Am. J. Respir. Cell Mol. Biol. 12: 540-546 [Abstract].
36.
Bonecini-Almeida, M. G.,
S. Chitale,
I. Boutsikakis,
J. Geng,
H. Doo,
S. He, and
J. L. Ho.
1998.
Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-
and primed lymphocytes.
J. Immunol.
160:
4490-4499
37. Nozaki, Y., Y. Hasegawa, S. Ichiyama, I. Nakashima, and K. Shimokata. 1997. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect. Immun. 65: 3644-3647 [Abstract].
38.
Kuo, H.-P.,
C.-H. Wang,
K.-S. Huang,
H.-C. Lin,
C.-T. Yu,
C.-Y. Liu, and
L.-C. Lu.
2000.
Nitric oxide modulates interleukin-1
and tumor necrosis
factor-
synthesis by alveolar macrophages in pulmonary tuberculosis.
Am. J. Respir. Crit. Care Med.
161:
192-199
39. Wang, C.-H., C.-Y. Liu, H.-C. Lin, C.-T. Yu, K.-F. Chung, and H.-P. Kuo. 1998. Increased exhaled nitric oxide in active pulmonary tuberculosis due to inducible NO synthase upregulation in alveolar macrophages. Eur. Respir. J. 11: 809-815 [Abstract].
40.
Facchetti, F.,
W. Vermi,
S. Fiorentini,
M. Chilosi,
A. Caruso,
M. Duse,
L. D. Notarangelo, and
R. Badolato.
1999.
Expression of inducible nitric oxide
synthase in human granulomas and histiocytic reactions.
Am. J. Pathol.
154:
145-152
41. Raju, B., E. Michailidis, A. Lubin, W. N. Rom, and R. Condos. 2000. Aerosolized interferon-gamma increases nitric oxide production in the bronchoalveolar lavage fluid of patients with active tuberculosis. Am. J. Respir. Crit. Care Med. 161: A759 .
42. Friedman, C. R., G. C. Quinn, B. N. Kreiswirth, D. C. Perlman, N. Salomon, N. Schluger, M. Lutfey, J. Berger, N. Poltoratskaia, and L. W. Riley. 1997. Widespread dissemination of a drug-susceptible strain of Mycobacterium tuberculosis. J. Infect. Dis. 176: 478-484 [Medline].
43. Robbins, R. A., P. J. Barnes, D. R. Springall, J. B. Warren, O. J. Kwon, L. D. K. Buttery, A. J. Wilson, D. A. Geller, and J. M. Polak. 1994. Expression of inducible nitric oxide in human lung epithelial cells. Biochem. Biophys. Res. Comm. 203: 209-218 [Medline].
44. Kwon, O. J., J. H. Kim, H. C. Kim, G. Y. Suh, J. W. Park, M. P. Chung, H. Kim, and C. H. Rhee. 1998. Nitric oxide expression in airway epithelial cells in response to tubercle bacilli stimulation. Respirology 3: 119-124 . [Medline]
45. Pasula, R., J. R. Wright, D. L. Kachel, and W. J. Martin. 1999. Surfactant protein A supresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis. J. Clin. Invest. 103: 483-490 [Medline].
46. Demangel, C., A. G. D. Bean, E. Martin, C. G. Feng, A. T. Kamath, and W. J. Britton. 1999. Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guerin-infected dendritic cells. Eur. J. Immunol. 29: 1972-1979 [Medline].
47. Henderson, R. A., S. C. Watkins, and J. L. Flynn. 1997. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J. Immunol. 159: 635-643 [Abstract].
48. Tascon, R. E., C. S. Soares, S. Ragno, E. Stavropoulos, E. M. A. Hirst, and M. J. Colston. 2000. Mycobacterium tuberculosis-activated dendritic cells induce protective immunity in mice. Immunology 99: 473-480 [Medline].
49.
Aiello, S.,
M. Noris,
G. Piccinini,
S. Tomasoni,
F. Casiraghi,
S. Bonazzola,
M. Mister,
M. H. Sayegh, and
G. Remuzzi.
2000.
Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response
to self- and alloantigens.
J. Immunol.
164:
4649-4658
50.
Lu, L.,
C. A. Bonham,
F. G. Chambers,
S. C. Watkins,
R. A. Hoffman,
R. L. Simmons, and
A. W. Thomson.
1996.
Induction of nitric oxide synthase in
mouse dendritic cells by IFN-
, endotoxin, and interaction with allogeneic
T cells.
J. Immunol.
157:
3577-3586
[Abstract].
51. Kradin, R. L., H. Sakamoto, F. I. Preffer, D. Dombkowski, K. M. Springer, and C. P. Leary. 2000. Accumulation of macrophages with dendritic cell characteristics in the pulmonary response to Listeria. Am. J. Respir. Crit. Care Med. 2000: 535-542 .
52.
Stenger, S.,
N. Donhauser,
H. Thuring,
M. Rollinghoff, and
C. Bogdan.
1996.
Reactivation of latent Leishmaniasis by inhibition of inducible nitric
oxide synthase.
J. Exp. Med.
183:
1501-1514
53. Chambers, M. A., B. G. Marshall, A. Wangoo, A. Bune, H. T. Cook, R. J. Shaw, and D. B. Young. 1997. Differential responses to challenge with live and dead Mycobacterium bovis Bacillus Calmette-Guerin. J. Immunol. 158: 1742-1748 [Abstract].
54.
Bodnar, K. A.,
N. V. Serbina, and
J. L. Flynn.
2001.
Fate of Mycobacterium
tuberculosis within murine dendritic cells.
Infect. Immun.
69:
800-809
55.
Munder, M.,
M. Mallo,
K. Eichmann, and
M. Modolell.
1998.
Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation.
J. Exp. Med.
187:
2103-2108
56. Cooper, A. M., C. D'Souza, A. A. Frank, and I. M. Orme. 1997. The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect. Immun. 65: 1317-1320 [Abstract].
57.
Nashleanas, M., and
P. Scott.
2000.
Activated T cells induce macrophages to
produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55.
Infect. Immun.
68:
1428-1434
58.
Reichmann, G.,
W. Walker,
E. N. Villegas,
L. Craig,
G. Cai,
J. Alexander, and
C. A. Hunter.
2000.
The CD40/CD40 ligand interaction is required for
resistance to toxoplasmic encephalitis.
Infect. Immun.
68:
1312-1318
59. Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40/CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis. Immunity 4: 263-273 .
60.
Campos-Neto, A.,
P. Ovendale,
T. Bement,
T. A. Koppi,
W. C. Fanslow,
M. A. Rossi, and
M. R. Alderson.
1998.
CD40 ligand is not essential for
the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis.
J. Immunol.
160:
2037-2041
61. Zhou, P., and R. A. Seder. 1998. CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with Histoplasma capsulatum. J. Exp. Med. 187: 1315-1324 .
62. Callard, R. E., R. J. Armitage, W. C. Fanslow, and M. K. Spriggs. 1993. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14: 559 [Medline].
63.
Sciorati, C.,
P. Rovere,
M. Ferrarini,
C. Paolucci,
S. Heltai,
R. Vaiani,
E. Clementi, and
A. A. Manfredi.
1999.
Generation of nitric oxide by the inducible nitric oxide synthase protects gamma delta T cells from Mycobacterium tuberculosis-induced apoptosis.
J. Immunol.
163:
1570-1576
64.
Nabeshima, S.,
M. Nomoto,
G. Matsuzaki,
K. Kishihara,
H. Taniguchi,
S. Yoshida, and
K. Nomoto.
1999.
T-cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with
Mycobacterium tuberculosis.
Infect. Immun.
67:
3221-3226
65.
Dalton, D. K.,
L. Haynes,
C. Q. Chu,
S. L. Swain, and
S. Wittmer.
2000.
Interferon gamma eliminates responding CD4 T cells during mycobacterial
infection by inducing apoptosis of activated CD4 T cells.
J. Exp. Med.
192:
117-122
66.
Chan, E. D.,
B. W. Winston,
S.-T. Uh,
M. W. Wynes,
D. M. Rose, and
D. W. H. Riches.
1999.
Evaluation of the role of mitogen-activated protein
kinases in the expression of inducible nitric oxide synthase by IFN
and
TNF
in mouse macrophages.
J. Immunol.
162:
415-422
67.
Adams, L. B.,
Y. Fukutomi, and
J. L. Krahenbuhl.
1993.
Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence.
Infect. Immun.
61:
4173-4181
68.
Zhang, Y.,
M. Doerfler,
T. C. Lee,
B. Guillemin, and
W. N. Rom.
1993.
Mechanisms of stimulation of interleukin-1
and tumor necrosis factor-
by Mycobacterium tuberculosis components.
J. Clin. Invest.
91:
2076-2083
.
69. Moreno, C., J. Taverne, A. Mehlert, C. A. W. Bate, R. J. Brealey, A. Meager, G. A. W. Rook, and J. H. L. Playfair. 1989. Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages. Clin. Exp. Immunol. 76: 240-245 [Medline].
70.
Chan, E. D.,
K. R. Morris,
J. T. Belisle,
P. Hill,
L. K. Remigio,
P. J. Brennan, and
D. W. H. Riches.
2001.
Induction of iNOS-NO by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK,
MKK7-JNK, and NF
B signaling pathways.
Infect. Immun.
69:
2001-2010
71. Barnes, P. F., D. Chatterjee, J. S. Abrams, S. Lu, E. Wang, M. Yamamura, P. J. Brennan, and R. L. Modlin. 1992. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. J. Immunol. 149: 541-547 [Abstract].
72.
Brightbill, H. D.,
D. H. Libraty,
S. R. Krutzik,
R.-B. Yang,
J. T. Belisle,
J. R. Bleharski,
M. Maitland,
M. V. Norgard,
S. E. Plevy,
S. T. Smale,
P. J. Brennan,
B. R. Bloom,
P. J. Godowski, and
R. L. Modlin.
1999.
Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors.
Science
285:
732-735
73.
Sikora, A.,
J. Liu,
C. Brosnan,
G. Buell,
I. Chessel, and
B. R. Bloom.
1999.
Purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism.
J. Immunol.
163:
558-561
74.
Ehrt, S.,
M. U. Shiloh,
J. Ruan,
M. Choi,
S. Gunzburg,
C. Nathan,
Q.-W. Xie, and
L. W. Riley.
1997.
A novel antioxidant gene from Mycobacterium
tuberculosis.
J. Exp. Med.
186:
1885-1896
75.
Ruan, J.,
G. St. John,
S. Ehrt,
L. Riley, and
C. Nathan.
1999.
noxR3, a novel
gene from Mycobacterium tuberculosis, protects Salmonella typhimurium
from nitrosative and oxidative stress.
Infect. Immun.
67:
3276-3283
76. Chen, L., Q.-W. Xie, and C. Nathan. 1998. Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. Mol. Cell 1: 795-805 . [Medline]
77.
Garbe, T. R.,
N. S. Hibler, and
V. Deretic.
1999.
Response to reactive nitrogen intermediates in Mycobacterium tuberculosis: induction of the 16-kilodalton alpha-crystallin homolog by exposure to nitric oxide donors.
Infect.
Immun.
67:
460-465
78. Wayne, L. G., and L. G. Hayes. 1998. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuberc. Lung Dis. 79: 127-132 .
79.
Serbina, N. V.,
C. C. Liu,
C. A. Scanga, and
J. L. Flynn.
2000.
CD8+ CTL
from lungs of Mycobacterium tuberculosis-infected mice express perforin
in vivo and lyse infected macrophages.
J. Immunol.
165:
353-363
80.
Stenger, S.,
D. A. Hanson,
R. Teitelbaum,
P. Dewan,
K. R. Niazi,
C. J. Froelich,
T. Ganz,
S. Thoma-Uszynski,
A. Melian,
C. Bogdan,
S. A. Porcelli,
B. R. Bloom,
A. M. Krensky, and
R. L. Modlin.
1998.
An antimicrobial activity of cytolytic T cells mediated by granulysin.
Science
282:
121-125
81.
Lewinsohn, D. M.,
T. T. Bement,
J. Xu,
D. H. Lynch,
K. H. Grabstein,
S. G. Reed, and
M. R. Alderson.
1998.
Human purified protein derivative-specific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms.
J. Immunol.
160:
2374-2379
82.
Ernst, W. A.,
S. Thoma-Uszynski,
R. Teitelbaum,
C. Ko,
D. A. Hanson,
C. Clayberger,
A. M. Krensky,
M. Leippe,
B. R. Bloom,
T. Ganz, and
R. L. Modlin.
2000.
Granulysin, a T cell product, kills bacteria by altering membrane permeability.
J. Immunol.
165:
7102-7108
This article has been cited by other articles:
![]() |
J. O. Jurado, I. B. Alvarez, V. Pasquinelli, G. J. Martinez, M. F. Quiroga, E. Abbate, R. M. Musella, H. E. Chuluyan, and V. E. Garcia Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis J. Immunol., July 1, 2008; 181(1): 116 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schmidt, T. H. Westhoff, P. Krauser, R. Ignatius, J. Jankowski, V. Jankowski, W. Zidek, and M. van der Giet The uraemic toxin phenylacetic acid impairs macrophage function Nephrol. Dial. Transplant., June 4, 2008; (2008) gfn266v3. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Sohaskey Nitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration J. Bacteriol., April 15, 2008; 190(8): 2981 - 2986. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Ly, M. I. Russell, and D. N. McMurray Cytokine Profiles in Primary and Secondary Pulmonary Granulomas of Guinea Pigs with Tuberculosis Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 455 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Niederweis Nutrient acquisition by mycobacteria Microbiology, March 1, 2008; 154(3): 679 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
|